-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SNA-11
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SNA-11 Drug Details SNA-11 is under development for the treatment of treatment resistant depression....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SNG-12
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SNG-12 Drug Details SNG-12 is under development for the treatment of major depression and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SND-51
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SND-51 Drug Details SND-51 is under development for the treatment of dementia and psychosis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sodium benzoate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sodium benzoate Drug Details Sodium benzoate (SND-1, SB-01, SR-01) is under development for the...
-
Product Insights
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Its signs and symptoms include sleep disturbances, including insomnia or sleeping too much, appetite changes, anxiety, agitation, or restlessness, and physical problems like back pain or headaches. Depression can be treated via antidepressants, mood stabilizers, or antipsychotics. The Depression pipeline market research report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...